aap Implantate is undergoing a strategic transition to being a pure trauma company and Q1 results, which were within guidance, set the scene for the group in its new shape. The completed sale of its biomaterials business (based on an assumed enterprise value of €36m), a drive to growth in Western Europe and the US and cost reshaping should support management’s guidance of 20% growth in trauma products and sales in the continued operation of €13-15m in FY16.
